Oral Abstracts—Tuesday, September 25, 2018OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 Published by Elsevier Inc.